BRIEF—China approval for RaQualia's tegoprazan

Nagoya, Japan-based RaQualia Pharma has received approval of its new drug application (NDA) in China for its acid-related gastrointestinal disease treatment tegoprazan, a potassium competitive acid blocker (P-CAB).

To be specific, the approval was granted to Shandong Luoxin Pharmaceutical, which in 2015 sub-licensed the drug from the Korean pharma HK inno.N , which had an exclusive licensing deal with Raqualia in 2010.

Raqualia will get an about 100 million yen ($800,000) milestone payment from the Seoul-based company, according to a statement.

Tegoprazan is expected to generate sales in China in late 2022.

The drug was launched in South Korea in 2019.

HK inno.N is also seeking partners in South East Asia and South America to explore opportunities for tegoprazan.